In this study, based on network pharmacology, further analysis was performed using RNA-seq, and we found J-NE may have a therapeutic effect on CGN via influencing the expression of CCL7, LCN2, CCL2, and CXCL1, consequently changing the inflammatory response and controlling the IL-17 signaling pathway. The gene discussed is LCN2; the disease is childhood gender nonconformity.